Format

Send to

Choose Destination
J Pathol. 2014 Nov;234(3):289-91. doi: 10.1002/path.4426.

PML nuclear bodies: regulation, function and therapeutic perspectives.

Author information

1
Université Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, Paris, France; INSERM UMR 944, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Institut Universitaire d'Hématologie, Hôpital St. Louis, Paris, France; CNRS UMR 7212, Hôpital St. Louis, Paris, France.

Abstract

PML nuclear bodies (NBs) were first described by electron microscopy and rediscovered through their treatment-reversible disruption in a rare leukaemia. They recruit multiple partner proteins and now emerge as interferon- and oxidative stress-responsive sumoylation factories. NBs mediate interferon-induced viral restriction, enhance proteolysis, finely tune metabolism and enforce stress-induced senescence. Apart from being markers of cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions, including cancer, viral infection or neurodegenerative diseases.

KEYWORDS:

PML; RNF4; arsenic; interferon; oxidative stress; p53; senescence

PMID:
25138686
DOI:
10.1002/path.4426
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center